SENS Research Foundation and Concerned Donors, LLC, Paul Bugge, and Dr. Gary Baskin are pleased to announce that the dispute regarding the use of donor funds has been amicably settled to their satisfaction.
Don’t miss our new super fun SRF and Life Noggin animation about zombie cells and the SENS damage repair approach!
This video describes our work on finding ways to slow down or even reverse the accumulation of senescent cells.
SRF is pleased to announce that Bill Liao has been appointed Chairman of the Board of Directors. He’s been serving as a Director and Board Secretary since the beginning of SRF. Bill Liao is a Chinese-Australian-Irish entrepreneur, investor, former diplomat, business mentor, author, passionate leader and speaker, with a distinguished record in business development and community activism.
Invitation for Dr. De Grey and Richard Heart to join the Board of Directors
We are proud to announce the recent publication by Sharma lab/ApoptoSENS team in the journal Aging describing an improved method for enriching primary NK cells from human peripheral blood and demonstrating the ability of those NK cells to eliminate senescent cells by recapitulating more physiological conditions and potential therapeutic interventions.
We are thrilled to announce the expansion of our Research Center to over 11,000 sq. feet with the addition of new lab and office space. This is more than doubling our current facility.
One way senescent cells accumulate is when one senescent cell turns a neighboring cell senescent through SASP secretion. SRF scientists have discovered that these secondary senescent cells are resistant to the classic senolytic drugs. However, they have identified a new senolytic strategy that kills these senescent cells.
A supporter asks us if it would accelerate research progress much faster if did most testing in far shorter-lived animals, like the roundworm C. elegans or the fruit fly Drosophila – rather than mice.
Scientists at SENS Research Foundation led by Dr. Tesfahun (Tes) Dessale Admasu have just published their exciting new senolytic strategy to destroy a wider range of senescent cells than has up to now been possible.
Metformin has been proposed as an “anti-aging drug,” and scientists are organizing TAME, a major clinical trial to test the idea. In the final installment of this 5-part series, we look at TAME itself: how it’s structured, how it’s justified, and how the results could impact the push for longevity therapeutics.
A supporter asks us to elaborate on projects other than allotopic expression (AE), that SRF has undertaken that are targeting mitochondrial dysfunction; and how they relate to the original strategy of allotopic expression?
Metformin has been proposed as an “anti-aging drug,” and scientists are organizing TAME, a major clinical trial to test the idea. In Part 4 of this 5-part series, we look at human data on metformin and neurodegenerative aging diseases.
A supporter asks about the investigative report in Science magazine that suggests the critical study identifying beta-amyloid oligomers as the key actors in Alzheimer’s disease may have been based on fraudulent data.
Metformin has been proposed as an “anti-aging drug,” and scientists are organizing TAME, a major clinical trial to test the idea. In Part 3 of this 5-part series, we look at human trials of metformin in prevention and treatment of cancer.
A supporter asks about how the central MitoSENS strategy can be delivered to our cells.
Metformin has been proposed as an “anti-aging drug,” and scientists are organizing TAME, a major clinical trial to test the idea. In Part 2 of this 5-part series, we look at some of the human studies on metformin, including a flawed observational study that created the illusion that diabetics on metformin actually live longer than people without diabetes.
Sign up to stay informed about the latest news and opportunities with SRF!
Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.
© 2024 SENS Research Foundation – ALL RIGHTS RESERVED
Sign up to stay informed about the latest news and opportunities with SRF!
Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.
© 2024 SENS Research Foundation – ALL RIGHTS RESERVED
